DRD2 and schizophrenia: The schizophrenia patients enrolled in our study received haloperidol, a highly effective and widely prescribed classical antipsychotic [85,86], which demonstrates the highest risk of AIP [6,87] due to the “tight” blockade of the DRD2 in the nigrostriatal pathway [11,12,14,15,88].